Published in Nat Rev Immunol on December 11, 2009
The role of ubiquitylation in immune defence and pathogen evasion. Nat Rev Immunol (2011) 1.76
Immuno- and constitutive proteasomes do not differ in their abilities to degrade ubiquitinated proteins. Cell (2013) 1.74
Proteasome activators. Mol Cell (2011) 1.62
Different affinity windows for virus and cancer-specific T-cell receptors: implications for therapeutic strategies. Eur J Immunol (2012) 1.41
Immunoproteasomes: structure, function, and antigen presentation. Prog Mol Biol Transl Sci (2012) 1.36
Aging and immune function: molecular mechanisms to interventions. Antioxid Redox Signal (2011) 1.18
Pharmacological targets in the ubiquitin system offer new ways of treating cancer, neurodegenerative disorders and infectious diseases. Expert Rev Mol Med (2011) 1.12
A dominant role for the immunoproteasome in CD8+ T cell responses to murine cytomegalovirus. PLoS One (2011) 1.08
Insights into the innate immunity of the Mediterranean mussel Mytilus galloprovincialis. BMC Genomics (2011) 1.05
Intrinsically disordered segments affect protein half-life in the cell and during evolution. Cell Rep (2014) 1.01
Deciphering preferential interactions within supramolecular protein complexes: the proteasome case. Mol Syst Biol (2015) 1.00
Overcoming bortezomib resistance in human B cells by anti-CD20/rituximab-mediated complement-dependent cytotoxicity and epoxyketone-based irreversible proteasome inhibitors. Exp Hematol Oncol (2013) 0.98
Inhibition of the immunoproteasome ameliorates experimental autoimmune encephalomyelitis. EMBO Mol Med (2014) 0.95
Genomic profiling of human Leishmania braziliensis lesions identifies transcriptional modules associated with cutaneous immunopathology. J Invest Dermatol (2014) 0.94
A selective inhibitor of the immunoproteasome subunit LMP2 induces apoptosis in PC-3 cells and suppresses tumour growth in nude mice. Br J Cancer (2012) 0.93
Proteasome immunosubunits protect against the development of CD8 T cell-mediated autoimmune diseases. J Immunol (2011) 0.93
Deletion of immunoproteasome subunits imprints on the transcriptome and has a broad impact on peptides presented by major histocompatibility complex I molecules. Mol Cell Proteomics (2010) 0.92
Dendritic cell-based vaccination in cancer: therapeutic implications emerging from murine models. Front Immunol (2015) 0.91
Ubiquitin-independent proteosomal degradation of myelin basic protein contributes to development of neurodegenerative autoimmunity. FASEB J (2015) 0.90
Interferon-γ-induced upregulation of immunoproteasome subunit assembly overcomes bortezomib resistance in human hematological cell lines. J Hematol Oncol (2014) 0.89
Assembly of the 20S proteasome. Biochim Biophys Acta (2013) 0.88
Gamma interferon and perforin control the strength, but not the hierarchy, of immunodominance of an antiviral CD8+ T cell response. J Virol (2011) 0.88
The immunoproteasome and viral infection: a complex regulator of inflammation. Front Microbiol (2015) 0.86
Human thymic epithelial primary cells produce exosomes carrying tissue-restricted antigens. Immunol Cell Biol (2015) 0.86
Activity-based near-infrared fluorescent probe for LMP7: a chemical proteomics tool for the immunoproteasome in living cells. Chembiochem (2012) 0.85
Regulation of immunoproteasome function in the lung. Sci Rep (2015) 0.85
A bright approach to the immunoproteasome: development of LMP2/β1i-specific imaging probes. Bioorg Med Chem (2011) 0.83
The Thymic Orchestration Involving Aire, miRNAs, and Cell-Cell Interactions during the Induction of Central Tolerance. Front Immunol (2015) 0.82
The proteasome system in infection: impact of β5 and LMP7 on composition, maturation and quantity of active proteasome complexes. PLoS One (2012) 0.82
Prophylactic and therapeutic efficacies of a selective inhibitor of the immunoproteasome for Hashimoto's thyroiditis, but not for Graves' hyperthyroidism, in mice. Clin Exp Immunol (2012) 0.82
Thymoproteasomes produce unique peptide motifs for positive selection of CD8(+) T cells. Nat Commun (2015) 0.82
Regulation rewiring analysis reveals mutual regulation between STAT1 and miR-155-5p in tumor immunosurveillance in seven major cancers. Sci Rep (2015) 0.82
PA28αβ: the enigmatic magic ring of the proteasome? Biomolecules (2014) 0.81
The immunoproteasome in steatohepatitis: its role in Mallory-Denk body formation. Exp Mol Pathol (2011) 0.81
Comparative genomic analysis of the proteasome β5t subunit gene: implications for the origin and evolution of thymoproteasomes. Immunogenetics (2011) 0.81
Proteasome subtypes and regulators in the processing of antigenic peptides presented by class I molecules of the major histocompatibility complex. Biomolecules (2014) 0.79
Activity-based imaging probes of the proteasome. Cell Biochem Biophys (2013) 0.79
Immunoproteasome dysfunction augments alternative polarization of alveolar macrophages. Cell Death Differ (2016) 0.79
Clinical activity of carfilzomib correlates with inhibition of multiple proteasome subunits: application of a novel pharmacodynamic assay. Br J Haematol (2016) 0.78
Epitope Prediction Assays Combined with Validation Assays Strongly Narrows down Putative Cytotoxic T Lymphocyte Epitopes. Vaccines (Basel) (2015) 0.77
Association Analysis of Proteasome Subunits and Transporter Associated with Antigen Processing on Chinese Patients with Parkinson's Disease. Chin Med J (Engl) (2016) 0.77
Modelling proteasome and proteasome regulator activities. Biomolecules (2014) 0.77
Inhibiting the immunoproteasome exacerbates the pathogenesis of systemic Candida albicans infection in mice. Sci Rep (2016) 0.77
Erythropoietic defect associated with reduced cell proliferation in mice lacking the 26S proteasome shuttling factor Rad23b. Mol Cell Biol (2013) 0.76
A humanized yeast proteasome identifies unique binding modes of inhibitors for the immunosubunit β5i. EMBO J (2016) 0.76
Trypanosoma cruzi infection down-modulates the immunoproteasome biosynthesis and the MHC class I cell surface expression in HeLa cells. PLoS One (2014) 0.76
Endometrial factors similarly induced by IFNT2 and IFNTc1 through transcription factor FOXS1. PLoS One (2017) 0.75
Extracellular proteasome-osteopontin circuit regulates cell migration with implications in multiple sclerosis. Sci Rep (2017) 0.75
Proteasome subunit expression analysis and chemosensitivity in relapsed paediatric acute leukaemia patients receiving bortezomib-containing chemotherapy. J Hematol Oncol (2016) 0.75
Anti-viral immune responses in a primitive lung: characterization and expression analysis of interferon-inducible immunoproteasome subunits LMP2, LMP7 and MECL-1 in a sarcopterygian fish, the Nigerian spotted lungfish (Protopterus dolloi). Dev Comp Immunol (2013) 0.75
In vitro co-culture systems for studying molecular basis of cellular interaction between Aire-expressing medullary thymic epithelial cells and fresh thymocytes. Biol Open (2014) 0.75
Dysregulation of the (immuno)proteasome pathway in malformations of cortical development. J Neuroinflammation (2016) 0.75
The Brain Proteome of the Ubiquitin Ligase Peli1 Knock-Out Mouse during Experimental Autoimmune Encephalomyelitis. J Proteomics Bioinform (2016) 0.75
Loss of recognition by cross-reactive T cells and its relation to a C-terminus-induced conformational reorientation of an HLA-B*2705-bound peptide. Protein Sci (2010) 0.75
Proteasome Activity Profiling Uncovers Alteration of Catalytic β2 and β5 Subunits of the Stress-Induced Proteasome during Salinity Stress in Tomato Roots. Front Plant Sci (2017) 0.75
Elucidating the catalytic subunit composition of distinct proteasome subtypes: a crosslinking approach employing bifunctional activity-based probes. Chembiochem (2014) 0.75
Proteasome function is not impaired in healthy aging of the lung. Aging (Albany NY) (2015) 0.75
Differential expression of 26S proteasome subunits and functional activity during neonatal development. Biomolecules (2014) 0.75
Discovery of Highly Selective Inhibitors of the Immunoproteasome Low Molecular Mass Polypeptide 2 (LMP2) Subunit. ACS Med Chem Lett (2017) 0.75
Inhibition and deficiency of the immunoproteasome subunit LMP7 suppress the development and progression of colorectal carcinoma in mice. Oncotarget (2017) 0.75
The ongoing saga of the mechanism(s) of MHC class I-restricted cross-presentation. Curr Opin Immunol (2017) 0.75
SYFPEITHI: database for MHC ligands and peptide motifs. Immunogenetics (1999) 14.15
Cellular responses to interferon-gamma. Annu Rev Immunol (1997) 13.23
Crystal structure of the 20S proteasome from the archaeon T. acidophilum at 3.4 A resolution. Science (1995) 12.94
Structure of 20S proteasome from yeast at 2.4 A resolution. Nature (1997) 12.73
Inhibitors of the proteasome block the degradation of most cell proteins and the generation of peptides presented on MHC class I molecules. Cell (1994) 11.73
The biological functions of T helper 17 cell effector cytokines in inflammation. Immunity (2008) 10.55
Recognition and processing of ubiquitin-protein conjugates by the proteasome. Annu Rev Biochem (2009) 8.83
Ablation of "tolerance" and induction of diabetes by virus infection in viral antigen transgenic mice. Cell (1991) 6.49
Cross-presentation, dendritic cell subsets, and the generation of immunity to cellular antigens. Immunol Rev (2004) 3.98
Gamma-interferon and expression of MHC genes regulate peptide hydrolysis by proteasomes. Nature (1993) 3.65
Proteasome from Thermoplasma acidophilum: a threonine protease. Science (1995) 3.62
The structure of the mammalian 20S proteasome at 2.75 A resolution. Structure (2002) 3.44
MHC-linked LMP gene products specifically alter peptidase activities of the proteasome. Nature (1993) 3.18
MHC class I expression in mice lacking the proteasome subunit LMP-7. Science (1994) 3.17
Regulation of CD8+ T cell development by thymus-specific proteasomes. Science (2007) 3.11
Structural basis for the activation of 20S proteasomes by 11S regulators. Nature (2000) 3.04
The repertoire of T cells shaped by a single MHC/peptide ligand. Cell (1996) 3.04
Antigen processing by the proteasome. Nat Rev Mol Cell Biol (2001) 2.93
A proteasome-related gene between the two ABC transporter loci in the class II region of the human MHC. Nature (1991) 2.84
A selective inhibitor of the immunoproteasome subunit LMP7 blocks cytokine production and attenuates progression of experimental arthritis. Nat Med (2009) 2.62
Structural and serological similarity of MHC-linked LMP and proteasome (multicatalytic proteinase) complexes. Nature (1991) 2.56
Identification, purification, and characterization of a protein activator (PA28) of the 20 S proteasome (macropain). J Biol Chem (1992) 2.48
Altered peptidase and viral-specific T cell response in LMP2 mutant mice. Immunity (1994) 2.39
Purification of an 11 S regulator of the multicatalytic protease. J Biol Chem (1992) 2.35
A role for the proteasome regulator PA28alpha in antigen presentation. Nature (1996) 2.30
Second proteasome-related gene in the human MHC class II region. Nature (1991) 2.29
Immunoproteasomes shape immunodominance hierarchies of antiviral CD8(+) T cells at the levels of T cell repertoire and presentation of viral antigens. J Exp Med (2001) 2.28
Discrete cleavage motifs of constitutive and immunoproteasomes revealed by quantitative analysis of cleavage products. J Exp Med (2001) 2.27
Interferon gamma stimulation modulates the proteolytic activity and cleavage site preference of 20S mouse proteasomes. J Exp Med (1994) 2.13
Interferon-gamma induces different subunit organizations and functional diversity of proteasomes. J Biochem (1994) 2.06
Subunit of the '20S' proteasome (multicatalytic proteinase) encoded by the major histocompatibility complex. Nature (1991) 1.97
Coordinated dual cleavages induced by the proteasome regulator PA28 lead to dominant MHC ligands. Cell (1996) 1.76
Immunoproteasomes largely replace constitutive proteasomes during an antiviral and antibacterial immune response in the liver. J Immunol (2001) 1.66
Immunoproteasome assembly and antigen presentation in mice lacking both PA28alpha and PA28beta. EMBO J (2001) 1.65
Identification of MECL-1 (LMP-10) as the third IFN-gamma-inducible proteasome subunit. J Immunol (1996) 1.62
Newly identified pair of proteasomal subunits regulated reciprocally by interferon gamma. J Exp Med (1996) 1.46
cDNA cloning and interferon gamma down-regulation of proteasomal subunits X and Y. Science (1994) 1.43
Simultaneous binding of PA28 and PA700 activators to 20 S proteasomes. Biochem J (1998) 1.42
Incorporation of major histocompatibility complex--encoded subunits LMP2 and LMP7 changes the quality of the 20S proteasome polypeptide processing products independent of interferon-gamma. Eur J Immunol (1995) 1.40
A third interferon-gamma-induced subunit exchange in the 20S proteasome. Eur J Immunol (1996) 1.35
An altered T cell repertoire in MECL-1-deficient mice. J Immunol (2006) 1.25
T cells lacking immunoproteasome subunits MECL-1 and LMP7 hyperproliferate in response to polyclonal mitogens. J Immunol (2006) 1.23
The final touches make perfect the peptide-MHC class I repertoire. Immunity (2007) 1.23
Immunoproteasome-deficient mice mount largely normal CD8+ T cell responses to lymphocytic choriomeningitis virus infection and DNA vaccination. J Immunol (2005) 1.23
Immunoproteasomes down-regulate presentation of a subdominant T cell epitope from lymphocytic choriomeningitis virus. J Immunol (2004) 1.21
Differential influence on cytotoxic T lymphocyte epitope presentation by controlled expression of either proteasome immunosubunits or PA28. J Exp Med (2000) 1.15
Thymoproteasome: probable role in generating positively selecting peptides. Curr Opin Immunol (2008) 1.14
Immunoproteasome subunit deficiencies impact differentially on two immunodominant influenza virus-specific CD8+ T cell responses. J Immunol (2006) 1.14
Development of proteasome inhibitors in oncology and autoimmune diseases. Curr Opin Drug Discov Devel (2008) 1.14
Structural plasticity of the proteasome and its function in antigen processing. Crit Rev Immunol (2001) 1.10
Immunoproteasomes are essential for clearance of Listeria monocytogenes in nonlymphoid tissues but not for induction of bacteria-specific CD8+ T cells. J Immunol (2006) 1.02
Expression of housekeeping and immunoproteasome subunit genes is differentially regulated in positively and negatively selecting thymic stroma subsets. Eur J Immunol (2004) 1.02
Lysine 188 substitutions convert the pattern of proteasome activation by REGgamma to that of REGs alpha and beta. EMBO J (2001) 1.02
Regulation of immunoproteasome subunit expression in vivo following pathogenic fungal infection. J Immunol (2002) 1.00
Proteasomes shape the repertoire of T cells participating in antigen-specific immune responses. Proc Natl Acad Sci U S A (2006) 0.99
The proteasome immunosubunit multicatalytic endopeptidase complex-like 1 is a T-cell-intrinsic factor influencing homeostatic expansion. Infect Immun (2007) 0.96
Critical role for the immunoproteasome subunit LMP7 in the resistance of mice to Toxoplasma gondii infection. Eur J Immunol (2009) 0.93
Dextran sulfate sodium-induced colitis is associated with enhanced low molecular mass polypeptide 2 (LMP2) expression and is attenuated in LMP2 knockout mice. Dig Dis Sci (2006) 0.90
Exclusive expression of proteasome subunit {beta}5t in the human thymic cortex. Blood (2009) 0.88
Antitumor activity of PR-171, a novel irreversible inhibitor of the proteasome. Cancer Res (2007) 3.85
A selective inhibitor of the immunoproteasome subunit LMP7 blocks cytokine production and attenuates progression of experimental arthritis. Nat Med (2009) 2.62
Nonproteasomal targets of the proteasome inhibitors bortezomib and carfilzomib: a link to clinical adverse events. Clin Cancer Res (2011) 2.56
Beneficial effect of novel proteasome inhibitors in murine lupus via dual inhibition of type I interferon and autoantibody-secreting cells. Arthritis Rheum (2012) 2.03
Immuno- and constitutive proteasome crystal structures reveal differences in substrate and inhibitor specificity. Cell (2012) 1.83
Immuno- and constitutive proteasomes do not differ in their abilities to degrade ubiquitinated proteins. Cell (2013) 1.74
The immunoproteasome in antigen processing and other immunological functions. Curr Opin Immunol (2012) 1.52
Immunodominance of an antiviral cytotoxic T cell response is shaped by the kinetics of viral protein expression. J Immunol (2003) 1.52
Design and synthesis of an orally bioavailable and selective peptide epoxyketone proteasome inhibitor (PR-047). J Med Chem (2009) 1.50
Prevention of experimental colitis by a selective inhibitor of the immunoproteasome. J Immunol (2010) 1.36
Pharmacokinetics, pharmacodynamics, metabolism, distribution, and excretion of carfilzomib in rats. Drug Metab Dispos (2011) 1.35
A novel orally active proteasome inhibitor ONX 0912 triggers in vitro and in vivo cytotoxicity in multiple myeloma. Blood (2010) 1.25
Long-lived signal peptide of lymphocytic choriomeningitis virus glycoprotein pGP-C. J Biol Chem (2003) 1.18
Development of proteasome inhibitors in oncology and autoimmune diseases. Curr Opin Drug Discov Devel (2008) 1.14
PR-924, a selective inhibitor of the immunoproteasome subunit LMP-7, blocks multiple myeloma cell growth both in vitro and in vivo. Br J Haematol (2010) 1.11
Molecular mechanisms of bortezomib resistant adenocarcinoma cells. PLoS One (2011) 1.10
Validation of the proteasome as a therapeutic target in Plasmodium using an epoxyketone inhibitor with parasite-specific toxicity. Chem Biol (2012) 1.09
Cross-presentation of the long-lived lymphocytic choriomeningitis virus nucleoprotein does not require neosynthesis and is enhanced via heat shock proteins. J Immunol (2005) 1.06
Proteasome-based mechanisms of intrinsic and acquired bortezomib resistance in non-small cell lung cancer. Biochem Pharmacol (2011) 1.04
Inactivating PSMB5 mutations and P-glycoprotein (multidrug resistance-associated protein/ATP-binding cassette B1) mediate resistance to proteasome inhibitors: ex vivo efficacy of (immuno)proteasome inhibitors in mononuclear blood cells from patients with rheumatoid arthritis. J Pharmacol Exp Ther (2012) 1.02
Complex changes in cellular inositol phosphate complement accompany transit through the cell cycle. Biochem J (2004) 1.01
Immunoproteasome subunit LMP7 deficiency and inhibition suppresses Th1 and Th17 but enhances regulatory T cell differentiation. J Immunol (2012) 1.01
A cytomegalovirus inhibitor of gamma interferon signaling controls immunoproteasome induction. J Virol (2004) 0.99
Reactive glia show increased immunoproteasome activity in Alzheimer's disease. Brain (2013) 0.99
Overcoming bortezomib resistance in human B cells by anti-CD20/rituximab-mediated complement-dependent cytotoxicity and epoxyketone-based irreversible proteasome inhibitors. Exp Hematol Oncol (2013) 0.98
Reduced immunoproteasome formation and accumulation of immunoproteasomal precursors in the brains of lymphocytic choriomeningitis virus-infected mice. J Immunol (2010) 0.96
Inhibition of the immunoproteasome ameliorates experimental autoimmune encephalomyelitis. EMBO Mol Med (2014) 0.95
Carfilzomib and ONX 0912 inhibit cell survival and tumor growth of head and neck cancer and their activities are enhanced by suppression of Mcl-1 or autophagy. Clin Cancer Res (2012) 0.94
The next generation proteasome inhibitors carfilzomib and oprozomib activate prosurvival autophagy via induction of the unfolded protein response and ATF4. Autophagy (2012) 0.92
Immunoproteasomes are essential for survival and expansion of T cells in virus-infected mice. Eur J Immunol (2010) 0.92
Interferon-γ-induced upregulation of immunoproteasome subunit assembly overcomes bortezomib resistance in human hematological cell lines. J Hematol Oncol (2014) 0.89
Higher ratio immune versus constitutive proteasome level as novel indicator of sensitivity of pediatric acute leukemia cells to proteasome inhibitors. Haematologica (2013) 0.89
The antiviral immune response in mice devoid of immunoproteasome activity. J Immunol (2011) 0.85
Inhibition of the sarcoplasmic/endoplasmic reticulum Ca2+-ATPase by flavonoids: a quantitative structure-activity relationship study. IUBMB Life (2008) 0.83
Endocrine disrupting alkylphenols: structural requirements for their adverse effects on Ca2+ pumps, Ca2+ homeostasis & Sertoli TM4 cell viability. Chem Biol Interact (2008) 0.83
Attenuation of the cytotoxic T lymphocyte response to lymphocytic choriomeningitis virus in mice subjected to chronic social stress. Brain Behav Immun (2010) 0.81
Alkylphenol endocrine disrupters inhibit IP3-sensitive Ca2+ channels. Biochem Biophys Res Commun (2003) 0.75
Solid (concrete) evidence needs both cement and sand. Anesthesiology (2004) 0.75